Entropy Neurodynamics Fully Enrols First Cohort in IV Psilocin Binge Eating Trial

Tryptamine Therapeutics ( (AU:ENP) ) has provided an update.

Entropy Neurodynamics has fully enrolled the first six-patient cohort in its clinical trial of TRP-8803, an IV-infused psilocin therapy for binge eating disorder being conducted with Swinburne University, and has already begun enrolling the second cohort. Two patients in Cohort 1 have completed both dosing sessions, the remaining participants are progressing through baseline assessments and initial infusions, and Cohort 2 dosing will commence after completion of Cohort 1 dosing and follow-up.

The study’s primary endpoint is safety and tolerability over 12 weeks, with secondary measures including binge eating frequency, BMI, weight-related metrics and psychological parameters, and early patients have shown multi-domain improvements in eating behavior, mood and wellbeing. Management says these early signals have accelerated recruitment and validated both the controlled IV-psilocin approach and trial design, positioning TRP-8803 as a scalable, precision-dosed alternative to oral psilocybin in binge eating disorder and potentially broader neuropsychiatric markets.

The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited is a clinical-stage biotechnology company developing proprietary psilocin-based therapies combined with psychotherapy for diseases with unmet medical needs. Its lead program, TRP-8803, is an intravenous psilocin formulation designed to improve on oral psilocybin by enabling faster onset, tighter control of the psychedelic experience and a shorter, more commercially feasible treatment duration. The company is leveraging prior Phase 2a trials of oral psilocybin in binge eating disorder, irritable bowel syndrome and fibromyalgia to advance TRP-8803 across neuropsychiatric indications.

Average Trading Volume: 2,462,492

Technical Sentiment Signal: Sell

Current Market Cap: A$54.87M

Learn more about ENP stock on TipRanks’ Stock Analysis page.